Table 2 Estimated prevalence of cardiovascular abnormalities.

Pre Hypertension

173, 16.6(14.4–18.9)

83, 16.0(12.9–19.2)

90, 17.2(14.0–20.5)

0.598

Hypertension

797, 76.9(74.2–79.4)

391, 75.6(71.9–79.3)

406, 78.0(74.4–81.5)

0.353

Self-reported

545, 68.4(65.2–71.6)

261, 66.8(62.1–71.4)

284, 70.0(65.5–74.4)

0.332

IFG

61, 5.8(4.4–7.3)

37, 7.1(4.9–9.4)

24, 4.6(2.8–6.4)

0.130

DM

209, 20.0(17.6–22.5)

111, 21.4(17.9–25.0)

98, 18.8(15.5–22.2)

0.285

Self-reported

123, 58.9(52.2–65.5)

58, 52.3(43.0–61.5)

65, 66.3(57.0–75.7)

0.039

Renal dysfunction

242, 23.3(20.7–25.9)

169, 32.6(28.6–36.6)

73, 14.1(11.1–17.1)

<0.001

  **

574, 55.3(52.3–58.3)

220, 42.6(38.3–46.8)

354, 67.9(63.9–72.0)

<0.001

Hyperuricemia

342, 33.0(30.1–35.8)

156, 30.2(26.2–34.1)

185, 35.6(31.4–39.6)

0.075

Persistant AF

54, 5.2(3.8–6.5)

31, 5.9(3.9–7.9)

23, 4.5(2.7–6.3)

0.316

Persistant Af

3, 0.3(0.0–0.6)

1, 0.2(−0.2–0.6)

2, 0.4(−0.1–0.9)

0.604

I AVB

64, 6.3(4.8–7.8)

38, 7.4(5.1–9.7)

27, 5.1(3.2–7.0)

0.137

II/III AVB

2, 0.2(−0.1–0.4)

2, 0.4(−0.1–0.9)

0

0.345

RBBB

106, 10.2(8.3–12.0)

55, 10.6(7.9–13.3)

51, 9.8(7.2–12.4)

0.663

LBBB

6, 0.6(0.1–1.0)

4, 0.8(0.0–1.5)

2, 0.4(−0.1–0.9)

0.788

Overweight

312, 30.0(27.3–32.8)

156, 30.2(26.2–34.1)

156, 29.9(26.0–33.9)

0.920

Obesity

98, 9.4(7.6–11.1)

41, 7.9(40.8–49.4)

57, 10.9(8.1–13.4)

0.138

Visceral Obesity

560, 54.5(51.5–57.6)

233, 45.1(5.6–10.3)

327, 62.7(58.6–66.9)

<0.001

Hypercholesterolaemia

367, 35.8(32.9–38.8)

144, 27.9(24.0–31.7)

223, 42.8(38.6–47.1)

<0.001

Hypertrigleicemiea

222, 21.6(18.9–23.9)

97, 18.8(15.4–22.1)

125, 24.0(20.3–27.7)

0.048

Hyper-low density lipoproteinemia

152, 14.9(12.8–17.1)

59, 11.4(8.7–14.2)

93, 17.9(14.6–21.1)

0.004

Hypo-high density lipoproteinemia

69, 6.5(5.1–8.2)

46, 8.9(6.4–11.4)

23, 4.5(2.7–6.2)

0.008